RxDoctor Payments DataLook up a doctor →

Judson Jones, NP

Nurse Practitioner · Baton Rouge, LANPI 1720492200

Payments from drug & device makers

$8,759in general payments, 2019–2025

Across 399 payments — averaging $21.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$849
  • Novartis$777
  • Daiichi Sankyo Inc.$493
  • Johnson & Johnson$391
  • Incyte Corporation$336
  • Merck$335
  • plus $6K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)37$849
Novartis46$777
Daiichi Sankyo Inc.20$493
Johnson & Johnson15$391
Incyte Corporation11$336
Merck15$335
Myriad Genetic Laboratories, Inc.4$317
Sanofi15$286
AbbVie9$271
Ipsen Biopharmaceuticals, Inc9$242
Lilly USA, LLC12$233
Pfizer12$226
Acrotech Biopharma Inc.4$211
AVEO Pharmaceuticals, Inc.10$204
Bayer10$204
E.r. Squibb & Sons, L.L.C.9$189
Amgen9$174
Exelixis Inc.8$152
Beigene USA, Inc.7$135
Pharmacyclics LLC, An Abbvie Company7$123
GSK6$120
Otsuka America Pharmaceutical, Inc.7$117
Pharmacosmos Therapeutics Inc.6$112
Akebia Therapeutics Inc6$111
Regeneron Healthcare Solutions, Inc.5$111
Bristol Myers Squibb6$108
Morphosys, US Inc.6$106
Genentech USA, Inc.5$105
Medtronic2$90
ADC Therapeutics America, Inc.4$87
Puma Biotechnology, Inc.5$86
Takeda Pharmaceuticals U.S.A., Inc.3$83
Adaptive Biotechnologies Corporation4$82
Gilead(2 entities)4$80
G1 Therapeutics, Inc.5$78
Servier Pharmaceuticals LLC4$78
Seagen Inc.4$78
Sanofi-aventis U.S. LLC1$75
EMD Serono, Inc.4$70
Blueprint Medicines Corporation3$69
Mallinckrodt Hospital Products Inc.3$61
Sobi, Inc2$56
Beone Medicines USA, Inc.3$55
Karyopharm Therapeutics Inc.3$53
Vifor Pharma, Inc.3$50
Fresenius USA Marketing, Inc.3$48
Jazz Pharmaceuticals Inc.2$43
Recordati_rare_diseases_inc.2$43
Eisai Inc.2$39
Astellas Pharma US Inc2$35
Ultragenyx Pharmaceutical Inc.2$32
Genmab U.S., Inc.1$30
OPKO Pharmaceuticals, LLC2$28
Sandoz1$26
Pharmaessentia USA Corporation1$25
Azurity Pharmaceuticals, Inc.1$21
Immunocore Limited1$21
Syndax Pharmaceuticals, Inc.1$20
Dendreon Pharmaceuticals LLC1$19
Stemline Therapeutics Inc.1$18

How this compares

$8,759 in reported general payments places this provider in the 95th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana →

Medicare billing

Part B allowed, 2024
$8,600
Medicare patients
108
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Baton Rouge

See the full list for Louisiana →

Where these figures come from

Is this you, or does something look wrong? →